Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay

Akihiro Muto, Shigehisa Mori, Hiromichi Matsushita, Norihiro Awaya, Hironori Ueno, Nobuyuki Takayama, Shin Ichiro Okamoto, Masahiro Kizaki, Yasuo Ikeda

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The chromosomal translocation (8;21)(q22;q22) in the AML M2 subtype according to the FAB classification, results in the production of a novel fusion gene AML1/ETO. The chimaeric AML1/ETO transcript is useful for the detection of minimal residual disease (MRD). Recently, several studies on the detection of AML1/ETO transcripts in t(8;21) AML have been reported. However, the clinical significance of a small number of AML1/ETO transcripts by a reverse transcription-polymerase chain reaction (RT-PCR) remains to be elucidated. We have developed a novel quantitative RT-competitive PCR assay and evaluated the clinical usefulness of this method by the monitoring of MRD in eight patients with t(8;21) AML. In four patients in first continuous complete remission (CR) the value of MRD was always <0.1 fg of the competitor dose throughout their courses, whereas in four relapsed patients there was an increase in the value of MRD to >0.1 fg of the competitor dose before cytogenetic relapse. We conclude that the detection of the presence of cells with AML1/ETO fusion transcripts by our RT-competitive PCR assay may be useful to monitor disease progression and to predict subsequent relapse.

Original languageEnglish
Pages (from-to)85-94
Number of pages10
JournalBritish Journal of Haematology
Volume95
Issue number1
DOIs
Publication statusPublished - 1996

Keywords

  • MAL1/ETO
  • RT-competitive PCR
  • chemotherapy
  • minimal residual disease (MRD)
  • t(8;21)

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay'. Together they form a unique fingerprint.

  • Cite this

    Muto, A., Mori, S., Matsushita, H., Awaya, N., Ueno, H., Takayama, N., Okamoto, S. I., Kizaki, M., & Ikeda, Y. (1996). Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. British Journal of Haematology, 95(1), 85-94. https://doi.org/10.1046/j.1365-2141.1996.d01-1877.x